Novo Nordisk: oral Wegovy recorded ~721,000 U.S. prescriptions in Q1
- Novo Nordisk heads into May 6 earnings with oral Wegovy as the focus after IQVIA data showed about 721,000 U.S. prescriptions in Q1. - The big tell is speed versus money — weekly U.S. scripts reached roughly 130,000, but many patients started on lower doses that generate less revenue. - That matters because Lilly’s Foundayo won FDA approval on April 1, ending Novo’s brief solo run in oral obesity drugs.
Weight-loss pills are suddenly the most important fight in obesity drugs. Novo Nordisk got to market first with oral Wegovy, and early demand looks real. But the easy part was getting doctors and patients interested. The hard part starts now — turning a flood of starter prescriptions into durable revenue before Eli Lilly uses its own pill to squeeze price, access, and market share. (money.usnews.com) ### Why is everyone staring at one prescription number? Because oral Wegovy’s Q1 launch looks stronger than expected. Analysts tracking IQVIA data put U.S. prescriptions at about 721,000 in the first quarter, which is a lot for a brand-new obesity pill and well above earlier launch expec(money.usnews.com)es. (globalbankingandfinance.com) ### Why doesn’t 721,000 scripts settle the story? Because not all prescriptions are worth the same amount. Early in a GLP-1 launch, lots of patients sit on lower starter doses while they titrate up, and those lower doses usually mean lower revenue per patient. Novo has also said U.S. supply rest(globalbankingandfinance.com) as the headline number suggests. (pharmaphorum.com) ### What changed in April? Novo lost its biggest launch advantage. On April 1, the FDA approved Eli Lilly’s Foundayo, also known as orforglipron, for chronic weight management in adults with obesity or overweight plus a related condition. That ended Novo’s short stretch as the only oral GLP-1 obesity pill on the U.S. market. (accessdata.fda.gov) ### Why is Lilly’s pill such a threat? Basically, it gives doctors and insurers another oral option right away. Foundayo’s launch started on April 9, and early reports said it had already reached about 20,000 patients within weeks, even before a full marketing push. In a market where rebates and formulary placement can swing demand fast, a second pill is not just competition — it is leverage. (biospace.com) ### Is this only about price? No — safety and compliance are moving to the center too. FDA approval for Foundayo came with the usual post-approval obligations that follow a new drug launch, and trade coverage says Lilly has been putting out more safety detail as regulators and invest(biospace.com)ly €108,766 over obesity-drug advertising campaigns. (medical.lilly.com) ### Why do the French fines matter outside France? Because they show how the market is maturing. A year ago, the story was mostly shortage and demand. Now the category is big enough that regulators are policing how these drugs are promoted, while payers are pushing harder on price and manufacturers are being forced to defend safety more explicitly. That is what happens when a hype market turns into a real one. (thelocal.fr) ### So what does Novo need to prove now? It needs to show that oral Wegovy is not just a flashy launch. The company has to prove patients are moving up dosing ladders, staying on therapy, and generating revenue fast enough to offset price pressure in the broader obesity market. If Wednesday’s results do not show that, the 721,000-script headline will start to look more like momentum than moat. (globalbankingandfinance.com) ### Bottom line Novo’s pill clearly found demand. But the story changed fast. This is no longer “can an obesity pill launch?” It already did. Now it is “can Novo hold the lane once Lilly is in it, prices are under pressure, and regulators are watching more closely?” (money.usnews.com)
